Loading…
Therapeutic Potential of Tranilast, an Anti-allergy Drug, in Proliferative Disorders
Tranilast (N-[3,4-dimethoxycinnamoyl]-anthranilic acid; Rizaben®) is an anti-allergy drug approved for use in Japan and South Korea, also used against asthma, autoimmune diseases, and atopic and fibrotic pathologies. The antitumor potential of tranilast is attracting considerable interest. This revi...
Saved in:
| Published in: | Anticancer research 2012-07, Vol.32 (7), p.2471-2478 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 2478 |
| container_issue | 7 |
| container_start_page | 2471 |
| container_title | Anticancer research |
| container_volume | 32 |
| creator | ROGOSNITZKY, Moshe DANKS, Rachel KARDASH, Elena |
| description | Tranilast (N-[3,4-dimethoxycinnamoyl]-anthranilic acid; Rizaben®) is an anti-allergy drug approved for use in Japan and South Korea, also used against asthma, autoimmune diseases, and atopic and fibrotic pathologies. The antitumor potential of tranilast is attracting considerable interest. This review summarizes recent evidence concerning the effect of tranilast on different tumor types and discusses the drug's possible mode of action in this area. In vivo and in vitro studies are covered, as well as evidence from clinical trials, in which tranilast was evaluated in various models of proliferative disorders. The findings presented in this report, demonstrate the excellent potential of tranilast in the management of certain types of tumor, and provide a strong rationale for the initiation of controlled clinical trials in this area. |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1023299562</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1023299562</sourcerecordid><originalsourceid>FETCH-LOGICAL-p241t-1de2c950f865dce80871fef1c6989c71dd3d2a1c5fc633b4827294735f19fd533</originalsourceid><addsrcrecordid>eNpF0MtKAzEUBuAgiq3VV5BsBBcdyGWSTJal9QYFuxjXQ5pLjaQzY5IRfHsDVlwdOHz8_OecgTkWEleCUXQO5ogwVAmE2AxcpfSBEOeyoZdgRkgRAtE5aNt3G9Vop-w13A3Z9tmrAAcH26h6H1TKS6h6uCr7SoVg4-EbbuJ0WELfw10cgnclIPsvCzc-DdHYmK7BhVMh2ZvTXIC3x4d2_VxtX59e1qttNZIa5wobS7RkyDWcGW0b1AjsrMO6tJRaYGOoIQpr5jSndF83RBBZC8ocls4wShfg_jd3jMPnZFPujj5pG4Lq7TClDiNCiZSMk0JvT3TaH63pxuiPKn53f58o4O4EVNIquHK99unfcdTUlHL6A0GwZ30</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1023299562</pqid></control><display><type>article</type><title>Therapeutic Potential of Tranilast, an Anti-allergy Drug, in Proliferative Disorders</title><source>EZB Electronic Journals Library</source><creator>ROGOSNITZKY, Moshe ; DANKS, Rachel ; KARDASH, Elena</creator><creatorcontrib>ROGOSNITZKY, Moshe ; DANKS, Rachel ; KARDASH, Elena</creatorcontrib><description>Tranilast (N-[3,4-dimethoxycinnamoyl]-anthranilic acid; Rizaben®) is an anti-allergy drug approved for use in Japan and South Korea, also used against asthma, autoimmune diseases, and atopic and fibrotic pathologies. The antitumor potential of tranilast is attracting considerable interest. This review summarizes recent evidence concerning the effect of tranilast on different tumor types and discusses the drug's possible mode of action in this area. In vivo and in vitro studies are covered, as well as evidence from clinical trials, in which tranilast was evaluated in various models of proliferative disorders. The findings presented in this report, demonstrate the excellent potential of tranilast in the management of certain types of tumor, and provide a strong rationale for the initiation of controlled clinical trials in this area.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 22753703</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject>Adult ; Animals ; Anti-Allergic Agents - pharmacology ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Cell Line, Tumor ; Clinical Trials as Topic ; Dermatology ; Female ; Humans ; Medical sciences ; Neoplasms - drug therapy ; ortho-Aminobenzoates - pharmacology ; ortho-Aminobenzoates - therapeutic use ; Skin involvement in other diseases. Miscellaneous. General aspects ; Tumors</subject><ispartof>Anticancer research, 2012-07, Vol.32 (7), p.2471-2478</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26084336$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22753703$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ROGOSNITZKY, Moshe</creatorcontrib><creatorcontrib>DANKS, Rachel</creatorcontrib><creatorcontrib>KARDASH, Elena</creatorcontrib><title>Therapeutic Potential of Tranilast, an Anti-allergy Drug, in Proliferative Disorders</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Tranilast (N-[3,4-dimethoxycinnamoyl]-anthranilic acid; Rizaben®) is an anti-allergy drug approved for use in Japan and South Korea, also used against asthma, autoimmune diseases, and atopic and fibrotic pathologies. The antitumor potential of tranilast is attracting considerable interest. This review summarizes recent evidence concerning the effect of tranilast on different tumor types and discusses the drug's possible mode of action in this area. In vivo and in vitro studies are covered, as well as evidence from clinical trials, in which tranilast was evaluated in various models of proliferative disorders. The findings presented in this report, demonstrate the excellent potential of tranilast in the management of certain types of tumor, and provide a strong rationale for the initiation of controlled clinical trials in this area.</description><subject>Adult</subject><subject>Animals</subject><subject>Anti-Allergic Agents - pharmacology</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cell Line, Tumor</subject><subject>Clinical Trials as Topic</subject><subject>Dermatology</subject><subject>Female</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Neoplasms - drug therapy</subject><subject>ortho-Aminobenzoates - pharmacology</subject><subject>ortho-Aminobenzoates - therapeutic use</subject><subject>Skin involvement in other diseases. Miscellaneous. General aspects</subject><subject>Tumors</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNpF0MtKAzEUBuAgiq3VV5BsBBcdyGWSTJal9QYFuxjXQ5pLjaQzY5IRfHsDVlwdOHz8_OecgTkWEleCUXQO5ogwVAmE2AxcpfSBEOeyoZdgRkgRAtE5aNt3G9Vop-w13A3Z9tmrAAcH26h6H1TKS6h6uCr7SoVg4-EbbuJ0WELfw10cgnclIPsvCzc-DdHYmK7BhVMh2ZvTXIC3x4d2_VxtX59e1qttNZIa5wobS7RkyDWcGW0b1AjsrMO6tJRaYGOoIQpr5jSndF83RBBZC8ocls4wShfg_jd3jMPnZFPujj5pG4Lq7TClDiNCiZSMk0JvT3TaH63pxuiPKn53f58o4O4EVNIquHK99unfcdTUlHL6A0GwZ30</recordid><startdate>20120701</startdate><enddate>20120701</enddate><creator>ROGOSNITZKY, Moshe</creator><creator>DANKS, Rachel</creator><creator>KARDASH, Elena</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20120701</creationdate><title>Therapeutic Potential of Tranilast, an Anti-allergy Drug, in Proliferative Disorders</title><author>ROGOSNITZKY, Moshe ; DANKS, Rachel ; KARDASH, Elena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p241t-1de2c950f865dce80871fef1c6989c71dd3d2a1c5fc633b4827294735f19fd533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Animals</topic><topic>Anti-Allergic Agents - pharmacology</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cell Line, Tumor</topic><topic>Clinical Trials as Topic</topic><topic>Dermatology</topic><topic>Female</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Neoplasms - drug therapy</topic><topic>ortho-Aminobenzoates - pharmacology</topic><topic>ortho-Aminobenzoates - therapeutic use</topic><topic>Skin involvement in other diseases. Miscellaneous. General aspects</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ROGOSNITZKY, Moshe</creatorcontrib><creatorcontrib>DANKS, Rachel</creatorcontrib><creatorcontrib>KARDASH, Elena</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ROGOSNITZKY, Moshe</au><au>DANKS, Rachel</au><au>KARDASH, Elena</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic Potential of Tranilast, an Anti-allergy Drug, in Proliferative Disorders</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2012-07-01</date><risdate>2012</risdate><volume>32</volume><issue>7</issue><spage>2471</spage><epage>2478</epage><pages>2471-2478</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>Tranilast (N-[3,4-dimethoxycinnamoyl]-anthranilic acid; Rizaben®) is an anti-allergy drug approved for use in Japan and South Korea, also used against asthma, autoimmune diseases, and atopic and fibrotic pathologies. The antitumor potential of tranilast is attracting considerable interest. This review summarizes recent evidence concerning the effect of tranilast on different tumor types and discusses the drug's possible mode of action in this area. In vivo and in vitro studies are covered, as well as evidence from clinical trials, in which tranilast was evaluated in various models of proliferative disorders. The findings presented in this report, demonstrate the excellent potential of tranilast in the management of certain types of tumor, and provide a strong rationale for the initiation of controlled clinical trials in this area.</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>22753703</pmid><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2012-07, Vol.32 (7), p.2471-2478 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1023299562 |
| source | EZB Electronic Journals Library |
| subjects | Adult Animals Anti-Allergic Agents - pharmacology Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Biological and medical sciences Cell Line, Tumor Clinical Trials as Topic Dermatology Female Humans Medical sciences Neoplasms - drug therapy ortho-Aminobenzoates - pharmacology ortho-Aminobenzoates - therapeutic use Skin involvement in other diseases. Miscellaneous. General aspects Tumors |
| title | Therapeutic Potential of Tranilast, an Anti-allergy Drug, in Proliferative Disorders |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T14%3A46%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20Potential%20of%20Tranilast,%20an%20Anti-allergy%20Drug,%20in%20Proliferative%20Disorders&rft.jtitle=Anticancer%20research&rft.au=ROGOSNITZKY,%20Moshe&rft.date=2012-07-01&rft.volume=32&rft.issue=7&rft.spage=2471&rft.epage=2478&rft.pages=2471-2478&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1023299562%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p241t-1de2c950f865dce80871fef1c6989c71dd3d2a1c5fc633b4827294735f19fd533%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1023299562&rft_id=info:pmid/22753703&rfr_iscdi=true |